Literature DB >> 10709783

CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway.

W Kasinrerk1, N Tokrasinwit, S Moonsom, H Stockinger.   

Abstract

CD99 is a 32 kDa cell surface glycoprotein which is involved in cell adhesion. Engagement of the CD99 molecule by CD99 monoclonal antibodies has been shown to induce homotypic aggregation of various cell types. By using a newly established CD99 monoclonal antibody, MT99/3, we show here that LFA-1/ICAM-1 independent cell adhesion pathways are activated via CD99. Engagement of the CD99 molecule by MT99/3 induced homotypic cell aggregation of Jurkat T-cells within 30 min reaching its maximal level within 4 h. The Jurkat cell aggregation was not blocked by addition of CD11a (LFA-1) and CD54 (ICAM-1) mAbs. Furthermore, MT99/3 treatment did not alter the expression of LFA-1 and ICAM-1 molecules. Induction of Jurkat homotypic aggregation by MT99/3 was, however blocked by the protein kinase C inhibitor, sphingosine, the protein tyrosine kinase inhibitor, genistein, and by actin filament polymerization blocking agent, cytochalasin B. Thus, these observations suggest that CD99 can mediate beta2-integrin independent cell adhesion that depends on activation of protein kinases and reorganization of the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709783     DOI: 10.1016/s0165-2478(99)00165-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  13 in total

1.  Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Authors:  Andrei Ivanov; Stephen A Beers; Claire A Walshe; Jamie Honeychurch; Waleed Alduaij; Kerry L Cox; Kathleen N Potter; Stephen Murray; Claude H T Chan; Tetyana Klymenko; Jekaterina Erenpreisa; Martin J Glennie; Tim M Illidge; Mark S Cragg
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 2.  Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.

Authors:  Marc El Beaino; Jason Roszik; John A Livingston; Wei-Lien Wang; Alexander J Lazar; Behrang Amini; Vivek Subbiah; Valerae Lewis; Anthony P Conley
Journal:  Curr Oncol Rep       Date:  2018-03-26       Impact factor: 5.075

3.  High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.

Authors:  Larizbeth A Romero; Takamitsu Hattori; Mohamed A E Ali; Gayatri Ketavarapu; Akiko Koide; Christopher Y Park; Shohei Koide
Journal:  J Mol Biol       Date:  2021-12-24       Impact factor: 5.469

4.  Association of CD99 short and long forms with MHC class I, MHC class II and tetraspanin CD81 and recruitment into immunological synapses.

Authors:  Supansa Pata; Pavel Otáhal; Tomáš Brdička; Witida Laopajon; Kodchakorn Mahasongkram; Watchara Kasinrerk
Journal:  BMC Res Notes       Date:  2011-08-13

5.  Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.

Authors:  Angela Oranger; Giacomina Brunetti; Claudia Carbone; Graziana Colaianni; Teresa Mongelli; Isabella Gigante; Roberto Tamma; Giorgio Mori; Adriana Di Benedetto; Marika Sciandra; Selena Ventura; Katia Scotlandi; Silvia Colucci; Maria Grano
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

6.  CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Authors:  Marika Sciandra; Maria Teresa Marino; Maria Cristina Manara; Clara Guerzoni; Maria Grano; Angela Oranger; Enrico Lucarelli; Pier-Luigi Lollini; Barbara Dozza; Loredana Pratelli; Maria Flavia Di Renzo; Mario Paolo Colombo; Piero Picci; Katia Scotlandi
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

Review 7.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Authors:  Maria Cristina Manara; Michela Pasello; Katia Scotlandi
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

Review 8.  CD99 at the crossroads of physiology and pathology.

Authors:  Michela Pasello; Maria Cristina Manara; Katia Scotlandi
Journal:  J Cell Commun Signal       Date:  2018-01-06       Impact factor: 5.782

9.  Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation.

Authors:  Nuchjira Takheaw; Papawadee Earwong; Witida Laopajon; Supansa Pata; Watchara Kasinrerk
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

10.  Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226.

Authors:  Minchan Gil; Hyo-Kyung Pak; Seo-Jeong Park; A-Neum Lee; Young-Soo Park; Hyangsin Lee; Hyunji Lee; Kyung-Eun Kim; Kyung Jin Lee; Dok Hyun Yoon; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immune Netw       Date:  2015-10-26       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.